TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
TORONTO and SAN DIEGO, April 18, 2016 -- Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2 proof-of-concept, and the Ontario Institute for Cancer Research (OICR), today announced positive results from a preclinical study of their CBZed-Nano™ (cabazitaxel cellulose nanoparticle) product in docetaxel-resistant prostate cancer mouse models. Preliminary results also showed that the nanoparticles accumulate in intracranial brain tumors in a mouse model of malignant glioma. These results were presented in a poster session during the American Association for Cancer Research (AACR) annual meeting in New Orleans, LA on April 18.
“We are encouraged by these results, because they indicate that in addition to the potential for better efficacy with CBZed-Nano™ than free cabazitaxel, they also indicate that our nanoparticle preparation may be better tolerated and can deliver drugs in the brain,” said Mohit Trikha, Ph.D., chief scientific officer, executive vice president and head of R&D at Triphase Accelerator. “With established manufacturing methodology and clear indications of improved outcomes, we anticipate continued study of CBZed-Nano™ in malignant glioma and other indications.”
In the orthotopic efficacy study, investigators injected mice femurs with a docetaxel-resistant prostate cancer strain. These mice were then injected with CBZed-Nano™ (55 mg/kg), conventional cabazitaxel (2 mg/kg) or vehicle in a conventional dosing regimen over 9 days. CBZed-Nano™ mice showed more than 120 days median survival, compared to the cabazitaxel group, which showed 47 days median survival. Efficacy was demonstrated equally with two preparations of CBZed-Nano™ using different manufacturing methodologies.
About Triphase Accelerator
Triphase Accelerator is a private drug development company with a primary focus on oncology and with operations in Toronto and San Diego. Triphase Accelerator is dedicated to advancing novel compounds through Phase 2 proof-of-concept clinical studies using a unique, science-based, high-quality model that is faster and more cost-effective than traditional pharmaceutical and biotech industry drug development approaches. Triphase Accelerator was spun out of the Ontario Institute for Cancer Research (OICR), with support from the Fight Against Cancer Innovation Trust (FACIT), MaRS Innovation and MaRS. It has a strategic relationship with Celgene for marizomib. For more information, visit www.triphaseco.com or LinkedIn.
Company Contact: Mohit Trikha, Ph.D., Chief Scientific Officer Triphase Accelerator Corporation [email protected] 858.242.1562 Media Contact: Jules Abraham JQA Partners, Inc. [email protected] 917-885-7378
